TREATMENT SET TS350393 injection, solution TREATMENT SET TS350394 injection, solution TREATMENT SET TS350533 injection, soluti

Šalis: Jungtinės Valstijos

kalba: anglų

Šaltinis: NLM (National Library of Medicine)

Veiklioji medžiaga:

PLANTAGO LANCEOLATA POLLEN (UNII: DO87T1U2CI) (PLANTAGO LANCEOLATA POLLEN - UNII:DO87T1U2CI), CHENOPODIUM ALBUM POLLEN (UNII: 098LKX5NCN) (CHENOPODIUM ALBUM POLLEN - UNII:098LKX5NCN), URTICA DIOICA POLLEN (UNII: DNB59M1NVU) (URTICA DIOICA POLLEN - UNII:DNB59M1NVU), AMARANTHUS RETROFLEXUS POLLEN (UNII: 73B14PX5FW) (AMARANTHUS RETROFLEXUS POLLEN - UNII:73B14PX5FW), AMBROSIA ARTEMISIIFOLIA POLLEN (UNII: K20Y81ACO3) (AMBROSIA ARTEMISIIFOLIA POLLEN - UNII:K20Y81ACO3), RUMEX ACETOSELLA POLLEN (UNII: N52MIQ81

Prieinama:

Antigen Laboratories, Inc.

INN (Tarptautinis Pavadinimas):

PLANTAGO LANCEOLATA POLLEN

Sudėtis:

PLANTAGO LANCEOLATA POLLEN 0.002 g in 1 mL

Vartojimo būdas:

SUBCUTANEOUS

Terapinės indikacijos:

When the natural exposure to elevated aeroallergens produces symptoms as described under Clinical Pharmacology, specific diagnosis and therapeutic procedures are indicated. Clearly, important clues to the cause of a person's allergic condition can be gleaned from a thorough history and careful physical examination. Diagnostic tests - in vitro or in vivo - serve only to confirm the physician's suspicions or to improve investigative skills. Specific diagnosis is especially indicated when the patient's symptoms are not controlled by medication. When immunotherapy is contemplated demonstration of sensitivity to a specific allergenic extract is necessary. An orderly approach to the use of diagnostic tests usually begins with direct skin testing. 5,6,11 THIS PRODUCT IS NOT INTENDED FOR TREATMENT OF PATIENTS WHO DO NOT MANIFEST IMMEDIATE HYPERSENSITIVITY REACTIONS TO THE ALLERGENIC EXTRACT FOLLOWING SKIN TESTING. There are no absolute contraindications; however, extreme caution is necessary when using diagnostic ski

Produkto santrauka:

Individual treatment sets as prescribed by the physician. The allergenic extract contains a variable number of individual doses depending on the patient's sensitivity and maximum tolerated maintenance treatment dose.

Autorizacija statusas:

Biologic Licensing Application

Prekės savybės

TREATMENT SET TS350393 - TREATMENT SET TS350393 INJECTION, SOLUTION
TREATMENT SET TS350394 - TREATMENT SET TS350394 INJECTION, SOLUTION
TREATMENT SET TS350533 - TREATMENT SET TS350533 INJECTION, SOLUTION
TREATMENT SET TS350534 - TREATMENT SET TS350534 INJECTION, SOLUTION
TREATMENT SET TS350535 - TREATMENT SET TS350535 INJECTION, SOLUTION
TREATMENT SET TS350565 - TREATMENT SET TS350565 INJECTION, SOLUTION
TREATMENT SET TS350566 - TREATMENT SET TS350566 INJECTION, SOLUTION
TREATMENT SET TS350619 - TREATMENT SET TS350619 INJECTION, SOLUTION
TREATMENT SET TS350622 - TREATMENT SET TS350622 INJECTION, SOLUTION
TREATMENT SET TS350623 - TREATMENT SET TS350623 INJECTION, SOLUTION
ANTIGEN LABORATORIES, INC.
----------
ALLERGENIC EXTRACTS
INDIVIDUAL TREATMENT VIAL
WARNINGS
INDIVIDUAL ALLERGENIC EXTRACT TREATMENT VIAL IS INTENDED FOR USE BY
PHYSICIANS WHO ARE
EXPERIENCED IN THE ADMINISTRATION OF ALLERGENIC EXTRACTS FOR
IMMUNOTHERAPY AND THE
EMERGENCY CARE OF ANAPHYLAXIS, OR FOR USE UNDER THE GUIDANCE OF AN
ALLERGY SPECIALIST.
INDIVIDUAL ALLERGENIC EXTRACT TREATMENT VIALS ARE NOT DIRECTLY
INTERCHANGEABLE WITH OTHER
ALLERGENIC EXTRACTS. THE INITIAL DOSE MUST BE BASED ON SKIN TESTING AS
DESCRIBED IN THE
DOSAGE AND ADMINISTRATION SECTION OF THIS INSERT. PATIENTS BEING
SWITCHED FROM OTHER TYPES
OF EXTRACT TO INDIVIDUAL TREATMENT VIALS SHOULD BE STARTED AS THOUGH
THEY WERE COMING UNDER
TREATMENT FOR THE FIRST TIME. PATIENTS SHOULD BE INSTRUCTED TO
RECOGNIZE ADVERSE REACTION
SYMPTOMS AND CAUTIONED TO CONTACT THE PHYSICIAN'S OFFICE IF REACTION
SYMPTOMS OCCUR. AS
WITH ALL ALLERGENIC EXTRACTS, SEVERE SYSTEMIC REACTIONS MAY OCCUR. IN
CERTAIN INDIVIDUALS,
THESE REACTIONS MAY BE LIFE-THREATENING. PATIENT SHOULD BE OBSERVED
FOR AT LEAST 20 MINUTES
FOLLOWING TREATMENT AND EMERGENCY MEASURES AS WELL AS PERSONNEL
TRAINED IN THEIR USE
SHOULD BE IMMEDIATELY AVAILABLE IN THE EVENT OF A LIFE-THREATENING
REACTION.
THIS PRODUCT SHOULD NOT BE INJECTED INTRAVENOUSLY. DEEP SUBCUTANEOUS
ROUTES HAVE PROVEN
TO BE SAFE. SEE THE WARNINGS, PRECAUTIONS, ADV